Compare BIO-TECHNE Corp (TECH) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Thomson Reuters Corp — how do they compare? BIO-TECHNE Corp trades at $72.46 (market cap $11.36B), while Thomson Reuters Corp trades at $101.45 (market cap $43.89B). The key difference: Thomson Reuters Corp is far larger — about 3.9× BIO-TECHNE Corp's market cap, and Thomson Reuters Corp pays the higher dividend (2.58%). Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 63 Days and Thomson Reuters Corp for 63 Days on average.
| TECH | TRI | |
|---|---|---|
Market Cap | $11.36B | $43.89B |
Volume | 5,390,331 | 1,648,199 |
Sector | Health | Industrials |
52-Week High | $72.61 | $163.45 |
52-Week Low | $43.31 | $76.55 |
Typical Hold Time | 63 Days | 63 Days |
Enterprise Value | $11.39B | $46.51B |
Dividend Yield | 0.44% | 2.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
Thomson Reuters (TRI) trades at $99.28, up 1.21% today, with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with 10% organic growth in core businesses and a 21.22% net income margin. Recent strategic moves include divesting its print unit to focus on technology offerings and launching its proprietary AI model, positioning for future growth.
TRI presents a compelling investment case with analyst consensus targeting $133.25 (34% upside) and strong institutional support. However, risks include recent cybersecurity incidents and margin compression from 2023 peaks. The company's shift toward AI and recurring revenue models supports long-term growth potential despite near-term execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
